UK value-based pricing plans in doubt
This article was originally published in SRA
Executive Summary
Value-based pricing, the UK's grand plan to reform the pricing of new medicines, seems to be in doubt, at least in its original form, according several sources close to discussions, including industry and NICE, the health technology appraisal institute for England and Wales.